Santarus, Inc. (NASDAQ:SNTS)

CAPS Rating: 2 out of 5

A pharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists or primary care physicians.

Recs

0
Player Avatar meghanjack (94.97) Submitted: 6/29/2007 10:37:57 AM : Outperform Start Price: $5.56 SNTS Score: +15.77

good drug

Featured Broker Partners


Advertisement